{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:45:04Z","timestamp":1788414304049,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ymthe.2021.08.020","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T23:29:58Z","timestamp":1628897398000},"page":"3512-3524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-4144","authenticated-orcid":false,"given":"Andrew D.","family":"Baik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0020-5375","authenticated-orcid":false,"given":"Philip","family":"Calafati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-6317","authenticated-orcid":false,"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina A.","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4056-0873","authenticated-orcid":false,"given":"Antonia","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1609-0154","authenticated-orcid":false,"given":"Sven","family":"Moller-Tank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Miloscio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Praggastis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Giovannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-1918","authenticated-orcid":false,"given":"Cheryl","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Mujica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barbounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Yanolatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9324-268X","authenticated-orcid":false,"given":"Nicholas","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6750-4308","authenticated-orcid":false,"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-2906","authenticated-orcid":false,"given":"Christos A.","family":"Kyratsous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6673-0589","authenticated-orcid":false,"given":"Christopher J.","family":"Schoenherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4152-4081","authenticated-orcid":false,"given":"Andrew J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6508-8942","authenticated-orcid":false,"given":"Aris N.","family":"Economides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-1353","authenticated-orcid":false,"given":"Katherine D.","family":"Cygnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.08.020_bib1","first-page":"3389","article-title":"Glycogen Storage Disease Type II: Acid Alpha-glucosidase (acid maltase) Deficiency","author":"Hirschhorn","year":"2000"},{"key":"10.1016\/j.ymthe.2021.08.020_bib2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2021.08.020_bib3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-Term Prognosis of Patients with Infantile-Onset Pompe Disease Diagnosed by Newborn Screening and Treated since Birth","volume":"166","author":"Chien","year":"2015","journal-title":"J.\u00a0Pediat"},{"key":"10.1016\/j.ymthe.2021.08.020_bib4","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.08.020_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2021.08.020_bib6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"McVie-Wylie","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2021.08.020_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: an industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.08.020_bib8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.08.020_bib9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.08.020_bib10","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid \u03b1-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.08.020_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2021.08.020_bib12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ymgme.2011.12.012","article-title":"Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction","volume":"105","author":"Coutinho","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2021.08.020_bib13","doi-asserted-by":"crossref","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.08.020_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.08.020_bib15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.08.020_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of Ert Via Immune Tolerance Induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev"},{"key":"10.1016\/j.ymthe.2021.08.020_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2008.010","article-title":"Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice","volume":"19","author":"Ziegler","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.08.020_bib18","doi-asserted-by":"crossref","first-page":"50336","DOI":"10.1074\/jbc.M409676200","article-title":"Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice","volume":"279","author":"Zhu","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.08.020_bib19","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.08.020_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/002215549704500404","article-title":"Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63, and alpha5beta1 integrin","volume":"45","author":"Sincock","year":"1997","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.ymthe.2021.08.020_bib21","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.yexcr.2008.09.020","article-title":"Trafficking and function of the tetraspanin CD63","volume":"315","author":"Pols","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ymthe.2021.08.020_bib22","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.08.020_bib23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1242\/jcs.106.4.1139","article-title":"Expression of alpha 7 integrin cytoplasmic domains during skeletal muscle development: alternate forms, conformational change, and homologies with serine\/threonine kinases and tyrosine phosphatases","volume":"106","author":"Song","year":"1993","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ymthe.2021.08.020_bib24","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.08.020_bib25","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.08.020_bib26","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.08.020_bib27","first-page":"446","article-title":"Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease","volume":"1","author":"Sun","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymthe.2021.08.020_bib28","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1093\/hmg\/ddn292","article-title":"Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease","volume":"17","author":"Raben","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.08.020_bib29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jgm.1372","article-title":"Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression","volume":"11","author":"Sun","year":"2009","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2021.08.020_bib30","first-page":"55","article-title":"Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?","volume":"39","author":"Broomfield","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2021.08.020_bib31","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1007\/s12035-017-0763-4","article-title":"A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice","volume":"55","author":"Lee","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymthe.2021.08.020_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40478-017-0464-2","article-title":"Long-Term Neurologic and Cardiac Correction by Intrathecal Gene Therapy in Pompe Disease","volume":"5","author":"Hordeaux","year":"2017","journal-title":"Acta Neuropathol. Commun"},{"key":"10.1016\/j.ymthe.2021.08.020_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/bit.21602","article-title":"Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier","volume":"99","author":"Boado","year":"2008","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ymthe.2021.08.020_bib34","doi-asserted-by":"crossref","first-page":"eaay1163","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","volume":"12","author":"Ullman","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.08.020_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ymthe.2021.08.020_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymgme.2014.12.001","article-title":"Therapies for the bone in mucopolysaccharidoses","volume":"114","author":"Tomatsu","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2021.08.020_bib37","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1128\/MCB.01163-08","article-title":"Deficiency of the tetraspanin CD63 associated with kidney pathology but normal lysosomal function","volume":"29","author":"Schr\u00f6der","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymthe.2021.08.020_bib38","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/mt.2008.72","article-title":"Gene Delivery to the Juvenile Mouse Liver Using Aav2\/8 Vectors","volume":"16","author":"Cunningham","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.08.020_bib39","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.08.020_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2021.08.020_bib41","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2021.08.020_bib42","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/mt.2014.114","article-title":"Liver-specific transcriptional modules identified by genome-wide in\u00a0silico analysis enable efficient gene therapy in mice and non-human primates","volume":"22","author":"Chuah","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.08.020_bib43","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in\u00a0situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.08.020_bib44","doi-asserted-by":"crossref","first-page":"13417","DOI":"10.1074\/jbc.M011481200","article-title":"The integrin alpha 7 cytoplasmic domain regulates cell migration, lamellipodia formation, and p130CAS\/Crk coupling","volume":"276","author":"Mielenz","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.08.020_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nbt1263","article-title":"F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses","volume":"25","author":"Poueymirou","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.08.020_bib46","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nbt822","article-title":"High-throughput engineering of the mouse genome coupled with high-resolution expression analysis","volume":"21","author":"Valenzuela","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.08.020_bib47","doi-asserted-by":"crossref","first-page":"15153","DOI":"10.1038\/ncomms15153","article-title":"Activin A more prominently regulates muscle mass in primates than does GDF8","volume":"8","author":"Latres","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621004147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621004147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:02:02Z","timestamp":1761501722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621004147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1525001621004147"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.08.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}